Cardiologyclinical trialpulmonary arterial hypertension
Evaluating Riociguat in Early Pulmonary Vascular Disease: Insights from the ESRA Phase IIa Trial
By MedXY|Jul 17, 2026
The ESRA trial demonstrates that riociguat is safe and effectively reduces pulmonary vascular resistance in early pulmonary vascular disease, though secondary benefits remain unproven in this early-stage, mostly connective tissue disease-as
